CHARLES TOWN, W.Va., July 18 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. , an emerging medical manufacturer of innovative technologies founded by world-renowned medical device inventor Dr. David B. Phillips, announced today that its securities have been cleared for public quotation on the Pink Sheets under the symbol RBRM.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )
ReBuilder Medical’s flagship product is its FDA registered, ReBuilder System for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) which focus on prescription drugs with powerful side effects, the ReBuilder System is a portable, battery powered medical device that provides a new non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
Over 20,000 patients have been treated using the cutting-edge technology of the ReBuilder System. It has a success rate that tops 95% and treats the cause as well as the symptoms. The treatment can be self-administered for less than $1.00 a day.
Twenty million, eight hundred thousand children and adults, or 7% of the U.S. population suffer from diabetes. Thirty percent of those diagnosed with diabetes will eventually suffer from peripheral neuropathy, pain and numbness in the feet and hands that can lead to complete loss of mobility, gangrene, and eventual amputations. $132 billion per year is the current cost of treating diabetes, or 1 of every 10 health care dollars spent. Neuropathy sufferers constitute 33% of this market, or 43.56 billion dollars in potential market. ReBuilder Medical Technologies, Inc. is a company in its infancy that has targeted 10% of this market, or, $43.56 million dollars in its next two market years, and expects to meet this goal. Its primary competition is from drug companies. Drug therapy has proven far less successful, and is prone to side-effects and addiction issues.
ReBuilder Medical also manufactures the Phillips Molluscum Treatment system for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum virus without any side effects. The company is currently performing research and development on a number of other medical products as well.
Dr. Phillips is CEO of ReBuilder Medical Technologies, Inc. located in Charles Town, WV. He is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System for the Early Detection of Breast Cancer (1980) and the AcuPen which detects acupuncture points electronically, and then treats them.
Dr. Phillips said, “We have seen significant growth in ReBuilder Medical over the past several years and public quotation was a logical step for us. We constantly develop our products to ensure they successfully alleviate the symptoms of peripheral neuropathy and molluscum contagiosum and public quotation will ensure that we are able to progress in our mission to help those suffering from those diseases.”
More information on ReBuilder Medical and its products can be found at: http://www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward- looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words “estimate,” “anticipate,” “expect,” “believe,” and similar expressions are intended to be forward-looking statements.
Photo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comReBuilder Medical Technologies, Inc.
CONTACT: David Phillips of ReBuilder Medical Technologies, Inc.,+1-304-725-2202
Web site: http://www.rebuildermedical.com/
